title: The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass.
abstract: The aim of this study was to determine whether the preoperative administration of lentinan, which is used clinically to activate T cell function in cancer patients, prevents the impairment of lymphocyte function after cardiopulmonary bypass (CPB). A total of 25 adults undergoing coronary artery bypass grafting were enrolled in this study. Lentinan (2 mg) was given to 10 randomly selected patients 7 d before surgery, while the other 15 patients were considered as a control. The white blood cell count, percentage of lymphocytes, subsets of lymphocytes, and natural killer cell activity were measured preoperatively, immediately after CPB and 1, 3, and 6 d after surgery. The white blood cell counts and the percentage of lymphocytes were not significantly different between the two groups; however, the percentage of CD4-positive cells in the lentinan group recovered to normal more rapidly than in the control group. Although natural killer cell activity was impaired in the control group after CPB, it maintained a nearly normal level in the lentinan group. The preoperative administration of lentinan for patients undergoing CPB ameliorated the impairment of natural killer activity and promoted the rapid recovery of CD4-positive cells.
authors.affiliation: First Department of Surgery, Yamaguchi University School of Medicine, Ube, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hamano
authors.forename: H
authors.initials: H
authors.lastname: Gohra
authors.forename: T
authors.initials: T
authors.lastname: Katoh
authors.forename: Y
authors.initials: Y
authors.lastname: Fujimura
authors.forename: N
authors.initials: N
authors.lastname: Zempo
authors.forename: K
authors.initials: K
authors.lastname: Esato
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000368:Aged; D016516:CD4-CD8 Ratio / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology*; D007912:Lentinan / Q000008:administration & dosage*; D007958:Leukocyte Count / Q000187:drug effects; D018655:Lymphocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011292:Premedication
chemical_list: D000276:Adjuvants, Immunologic; D007912:Lentinan